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Abstract
Background: Community and nosocomial infections by Pseudomonas aeruginosa still create a major therapeutic
challenge. The resistance of this opportunist pathogen to β-lactam antibiotics is determined mainly by production
of the inactivating enzyme AmpC, a class C cephalosporinase with a regulation system more complex than those
found in members of the Enterobacteriaceae family. This regulatory system also participates directly in
peptidoglycan turnover and recycling. One of the regulatory mechanisms for AmpC expression, recently identified
in clinical isolates, is the inactivation of LMM-PBP4 (Low-Molecular-Mass Penicillin-Binding Protein 4), a protein
whose catalytic activity on natural substrates has remained uncharacterized until now.
Results: We carried out in vivo activity trials for LMM-PBP4 of Pseudomonas aeruginosa on macromolecular
peptidoglycan of Escherichia coli and Pseudomonas aeruginosa. The results showed a decrease in the relative
quantity of dimeric, trimeric and anhydrous units, and a smaller reduction in monomer disaccharide pentapeptide
(M5) levels, validating the occurrence of D,D-carboxypeptidase and D,D-endopeptidase activities. Under conditions
of induction for this protein and cefoxitin treatment, the reduction in M5 is not fully efficient, implying that LMM-
PBP4 of Pseudomonas aeruginosa presents better behaviour as a D,D-endopeptidase. Kinetic evaluation of the direct
D,D-peptidase activity of this protein on natural muropeptides M5 and D45 confirmed this bifunctionality and the
greater affinity of LMM-PBP4 for its dimeric substrate. A three-dimensional model for the monomeric unit of LMM-
PBP4 provided structural information which supports its catalytic performance.
Conclusions: LMM-PBP4 of Pseudomonas aeruginosa is a bifunctional enzyme presenting both D,D-
carboxypeptidase and D,D-endopeptidase activities; the D,D-endopeptidase function is predominant. Our study
provides unprecedented functional and structural information which supports the proposal of this protein as a
potential hydrolase-autolysin associated with peptidoglycan maturation and recycling. The fact that mutant PBP4
induces AmpC, may indicate that a putative muropeptide-subunit product of the DD-EPase activity of PBP4 could
be a negative regulator of the pathway. This data contributes to understanding of the regulatory aspects of
resistance to β-lactam antibiotics in this bacterial model.
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Background
Pseudomonas aeruginosa behaves as an opportunist
pathogen capable of affecting a wide range of tissues and
generating clinical infection episodes which compromise
the host’s defence mechanisms [1]. Infections with
Pseudomonas aeruginosa represent a major therapeutic
challenge in which choice of the right antibiotic is fun-
damental, however this choice is complicated by the fact
that P. aeruginosa presents natural resistance to antibac-
terial agents to which it is not structurally related, and
can even acquire resistance during treatment [2, 3]. Bac-
terial resistance to β-lactam antibiotics is determined
mainly by the production of inactivating enzymes.
AmpC of P. aeruginosa is a naturally inducible enzyme.
Wild-type strains may be susceptible to anti-Pseudo-
monas penicillin, inhibitor-penicillin combinations,
cephalosporins and carbapenems, however in the pres-
ence of a β-lactam inducer, an increase in AmpC pro-
duction may cause resistance to almost all known β-
lactams, except carbapenems [4]. AmpC overproduction
may occur through reversible induction of ampC expres-
sion during exposure to certain β-lactams (cephamycins
and carbapenems) and β-lactamase inhibitors (clavulanic
acid). An important treatment fail occurs when ampC
regulation is lost due to de-repression, this condition
generally involves genetic mutations in proteins respon-
sible for regulating ampC expression [4, 5]. In P. aerugi-
nosa, ampC gene induction is closely connected to
peptidoglycan recycling, but regulation of the expression
is not yet fully understood [6]. Recycling of peptidogly-
can is a highly regulated system, allowing the bacterial
cell wall to be efficiently remodelled during growth and
division without its integrity being compromised. It has
been proposed that P. aeruginosa is capable of “sensing”
the disturbance of its cell wall, inducing expression of β-
lactamase AmpC and recovering homeostasis of the mu-
rein by hydrolysis of the antibiotic [7. During normal
growth and division, peptidoglycan fragments are elimi-
nated by autolysins to produce a series of periplasmic
peptides, GlcNAc-1,6-anhydroMurNAc-peptides (tri,
tetra or pentapeptides), transported to the cytoplasm
through AmpG and AmpP internal membrane perme-
ases [8]. In the cytoplasm, GlcNAc is eliminated from
the muropeptide by the action of NagZ (β-N-acetylglu-
cosaminidase), and the pool of 1,6-anhydroMurNAc-
peptides is recycled to form UDP-MurNAc-
pentapeptide, a precursor of peptidoglycan which will be
reincorporated into the murein of the cell wall. Tripep-
tide and pentapeptide species have been proposed as ef-
fector molecules which induce ampC transcription
through competitive binding with AmpR (LysR tran-
scriptional regulator) [7, 9]. In the absence of β-lactam
antibiotics, the cytoplasm concentration of 1,6-anhydro-
MurNAc-peptides is controlled by the activity of AmpD,
a N-acetylmuramoyl-L-alanine amidase which removes
the peptide chain from 1,6-anhydroMurNAc and
GlcNAc-1,6-anhydroMurNAc, reduces its concentration
and prevents overexpression of AmpC. Thus UDP-
MurNAc-pentapeptide predominates and binds to
AmpR, favouring repression of ampC transcription. Ex-
posure to β-lactams (inductors) stops peptidoglycan syn-
thesis and increases fragmentation, favouring the
accumulation of 1,6-anhydroMurNAc-peptides and
probably allowing tripeptide or pentapeptide species to
displace UDP-MurNAc-pentapeptide from the AmpR
regulator, determining the activation of the ampC gene
[7–9].
Penicillin-Binding Proteins (PBPs) are acyl-serin trans-
ferases, initially identified by their ability to form cova-
lent bonds with penicillin [10]. They are located on the
external face of the inner membrane and share common
D,D-peptidase activities (D,D-transpeptidase, D,D-car-
boxypeptidase or D,D-endopeptidase), catalysed by a do-
main which binds β-lactams (PB domain). The active
site of these proteins contains well preserved residues
with principal sequence S*xxK containing catalytic serin
and the SxN and KTG triads, which together allow
acetylation and deacetylation processes [11, 12]. PBPs
can be classified into two main categories as a function
of their amino acid sequence and relative mobility in
SDS-PAGE gels: high molecular mass PBPs (HMM-
PBPs, >60 kDa) and low molecular mass PBPs (LMM-
PBPs, <60 kDa). HMM-PBPs are responsible for the
polymerisation of peptidoglycan and its incorporation
into the pre-existing cell wall, while LMM-PBPs are in-
volved in peptidoglycan cell separation, maturation and
recycling, acting as catalyst for D,D-carboxypeptidase or
D,D-endopeptidase activities [13, 14]. Five HMM-PBPs
are recognised for the Pseudomonas aeruginosa model:
PBP1a, PBP1b, PBP2, PBP3 and PBP3a(3x); and three
LMM-PBPs: PBP4, PBP5(6) and PBP7, which are hom-
ologous with PBP1a, 1b, 2, 3, 4, 5 and 7 of E. coli. Only
the coding genes for PBP1a, 2, 3, 3a (3x) and 5 have
been cloned and characterised [15, 16]; the crystallo-
graphic structure has been resolved for HMM-PBP3 [17]
and LMM-PBP5 [12].
Modification of any protein involved in the ampC in-
duction mechanism may lead to de-repression of the ex-
pression of this gene. Although research into members
of the Enterobacteriaceae family has identified mutations
in ampR, the majority of the changes observed in clinical
isolations of P. aeruginosa have been associated with the
ampD gene [7 9, 18]. The AmpD protein has been char-
acterised as a negative AmpC regulator, however muta-
tions in the coding gene compromise normal processing
of anhydromuropeptides, producing a permanent in-
crease in the concentration of cytoplasm effectors which
favours binding with AmpR and raises the constitutive
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expression of ampC [2, 7, 19, 20]. A further complex-
ity for P. aeruginosa is that some strains which over-
produce AmpC do not present mutations in ampR
and ampD genes, or in the ampR-ampC inter-gene
region, and do not show changes in the expression
level of ampD, indicating the existence of additional
factors contributing to ampC regulation in this
model. Spontaneous inactivation of LMM-PBP4,
encoded by the dacB gene, has been recognised as a
clinically relevant cause of resistance to anti-Pseudo-
monas β-lactam antibiotics through hyperproduction
of AmpC, with levels exceeding those produced by
ampD mutants. Inactivation of this LMM-PBP pro-
vokes a highly efficient and complex response in
terms of β-lactam resistance, triggering overproduc-
tion of chromosomal AmpC β-lactamase and specific
activation of the two-components regulatory system
CreBC (BlrAB), which plays a role in resistance
through an still unknown mechanism [2 7, 21–23].
The connection between the peptidoglycan turnover
and recycling processes, and the regulatory pathways
for constitutive hyperproduction of chromosomal
AmpC β-lactamase, particularly the mechanism re-
lated with LMM-PBP4 inactivation, raised the need
for the present work, whose aim is to define the in
vivo functionality of this LMM-PBP of Pseudomonas
aeruginosa.
Methods
Bacterial strains, plasmids, phages and primers
The genotype and relevant phenotype of bacterial
strains, plasmids, and phages, and nucleotide sequences
of primers used in this study are given in Additional file
1: Tables S1, S2 and S3 [24–27].
Cloning, expression and purification of LMM-PBP4
Genomic DNA from the reference strain Pseudomonas
aeruginosa O1 (PAO1) was extracted and purified using
the Wizard® Genomic DNA Purification Kit (Promega);
the samples were quantified and stored at 4 °C. The
dacB gene (PA3047, GenBank accession number
AAG06435.1) was amplified using Touchdown PCR in a
MiniCycler™ PTC-150 (MJ Research) and the products
recovered, dacB-NdeI-HindIII, dacB-NdeI-HindIIITC,
dacB-NcoI-HindIII (~1.5 Kb) were purified, digested,
bound to expression vector pET-28b(+) and transformed
into electro-competent cells of E. coli BL21(DE3). Posi-
tive clones were recovered from transformant colonies
on Luria-Bertani (LB) agar plates supplemented with
kanamycin 30 μg/ml, and finally proved by sequencing.
Transformed E. coli BL21(DE3) containing pET-
PBP4HNC (PBP4 recombinant protein with carboxyl
and amino His-tag terminals), pET-PBP4HN (PBP4 re-
combinant protein with amino His-tag terminal) and
pET-PBP4HC (PBP4 recombinant protein with carboxyl
His-tag terminal) were cultured in LB medium supple-
mented with kanamycin 30 μg/ml to a DO600 of 0.4. Induc-
tion of protein expression was achieved by addition of
1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and in-
cubation for 60 min at 37 °C. Cells were then harvested
and frozen at −70 °C. To purify the expressed proteins, a
portion of the cell paste was thawed and suspended in
phosphate buffer saline (PBS) pH 8.0. Cells were disrupted
by two passes through a French® Pressure Cell Press (SLM
AMINCO) at 20,000 lb/in2, and the lysate was centrifuged
in a TL-100 (Beckman) ultracentrifuge at 70,000 rpm for
40 min at 4 °C. The resulting pellet was suspended in PBS
(pH 8.0) with 1 % Sarkosyl and stirred for 4 h at room
temperature. The insoluble material was separated by ultra-
centrifuging (80,000 rpm for 40 min at 20 °C) and the
supernatant (soluble extract) was dialyzed with PBS 1X,
Triton™ X-100 0.2 % pH 8.0 (solubilisation buffer) and
mixed with imidazole (20 mM final concentration). The di-
alyzed material was incubated in one volume of nickel resin
Ni-NTA Agarose (Qiagen), previously balanced in PBS 1X,
Triton™ X-100 0.2 %, imidazole 20 mM pH 8.0 (rinse buf-
fer) for 4 h at room temperature with gentle rotation. Un-
bound proteins were removed from the resin by washing
with rinse buffer three times. Proteins bound to the nickel-
resin were eluted stepwise with 3 ml each of 125 mM,
250 mM and 500 mM imidazole in solubilisation buffer.
The samples were dialyzed, aliquoted, quantified, concen-
trated (in units by Amicon® Ultra-4 Centrifugal Filter
30 kDa MWCO, Millipore) and stored at −20 °C. Fractions
of each purified recombinant protein identified as
PBP4HNC (NC-terminal His · tag), PBP4HN (N-terminal
His · tag) and PBP4HC (C-terminal His · tag), were analysed
using SDS-PAGE and immuno detection (western blot).
Cloning and expression of recombinant construct in
Pseudomonas aeruginosa
For cloning in an expression vector compatible with
Pseudomonas aeruginosa, the dacB coding gene was
amplified using defined primers together with gen-
omic DNA previously extracted and purified from ref-
erence strain PAO1. The amplification product dacB-
EcoRI-HindIII (~1.5 Kb) was cloned in pHERD26T
expression plasmid (Escherichia-Pseudomonas shuttle
vector). The pHERD-PBP4 recombinant clone was
transformed into electro competent Pseudomonas aer-
uginosa UCBPP-PA14 (PA14WT) cells, previously pre-
pared according to a protocol described by Choi et al.
[28]. Positive transformants (PA14WT/pHERD-PBP4
~ 7.7 Kb) recovered from colonies cultured on unsup-
plemented LB agar plates were purified and identified
by sequencing (dGTP BigDye® Terminator v3.0, Ap-
plied Biosystems). Overexpression was carried out
with L(+)-arabinose 0.2 % at 37 °C for 60 min.
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Preparation of bacterial envelopes and identification of
Penicillin-Binding Proteins
Membranes of E. coli BL21(DE3)/pET-PBP4HNC, E. coli
BL21(DE3)/pET-PBP4HN and E. coli BL21(DE3)/pET-
PBP4HC, with and without IPTG induction, were pre-
pared from a cell volume equivalent to 100 ml of culture
previously centrifuged at 10,500 rpm for 10 min at 4 °C
(Avanti™ J-25, Beckman Coulter). The pellet was re-
suspended in 3 ml of PBS 1X pH 8.0 and treated in an
ultrasonic homogenizer LABSONIC® M, Sartorius (4 cy-
cles of 60 s, amplitude 90 %). The sound-treated solution
was ultracentrifuged at 80,000 rpm for 40 min at 4 °C,
and the pellet from each sample (membrane fraction)
was re-suspended in 200 μl of PBS 1X pH 8.0 and stored
at −20 °C. The affinity and identification assays for
LMM-PBP4 were based on modifications of the proce-
dures described by Spratt & Pardee [29]. In β-lactam
binding assays, membrane extracts (50 μg) were incu-
bated with BOCILLIN™ FL Penicillin 10 μM (Life Tech-
nologies) for 30 min at 37 °C; the reaction was stopped
by incorporating 10 μl of NuPAGE® LDS Sample Buffer
4X with reducing agent (2-mercaptoethanol). Samples
were boiled for 10 min and the insoluble materials were
removed by centrifuging. Proteins in the samples were
separated by SDS-PAGE (NuPAGE® Novex® 8 % Bis-Tris
Midi Gel) and detected directly on the gels on a Ty-
phoon™ 9410 variable-mode imager (Amersham Biosci-
ences) at 488 nm with a 520BP40 emission filter. The
images obtained were processed with the ImageQuant™
TL programme v2003.02 (Amersham Biosciences) and
the fluorescent signal was measured in a GS-800™ Cali-
brated Densitometer (Bio-Rad) using the Quantity One®
1-D Analysis programme v4.6.3 (Bio-Rad).
Preparation of peptidoglycan
The peptidoglycan was prepared using a standard pro-
cedure described by Glauner [30]. Cultures in exponen-
tial growth phase in LB medium at 37 °C with aeration
were harvested by centrifuging for 15 min at 8500 rpm
at 4 °C; re-suspended in 4.5 ml of PBS 1X pH 8.0 and
slowly mixed with an equal volume of 6 % (wt/vol) boil-
ing SDS with vigorous stirring for 4 h and left overnight
with moderate stirring at room temperature. The insol-
uble fraction (peptidoglycan) was recovered by ultracen-
trifuging (80,000 rpm for 30 min at 25 °C) and re-
suspended in 3 ml of warm Milli-Q water; it was washed
repeatedly by re-suspension and ultracentrifuging
(80,000 rpm for 20 min at 25 °C) until complete elimin-
ation of the SDS present in the sample. The last pellet
was suspended in 900 μl of Tris–HCl 10 mM, NaCl
0.06 % pH 7.2 and digested first with 100 μg/ml α-
amylase at 37 °C for 90 min and then with 100 μg/ml of
preactivated pronase-E at 60 °C for 60 min. The en-
zymes were inactivated by boiling for 20 min in 1 %
(final concentration) SDS. The SDS was removed after
washing 3–4 times in Milli-Q water as described above.
The purified sacculus was stored in water at 4 °C until
use.
Preparation and separation of muropeptides
Macromolecular peptidoglycan was re-suspended in
500 μl of 50 mM phosphate buffer pH 4.9 and digested
with Cellosyl (Hoechst AG) 100 μg/ml final concentra-
tion at 37 °C overnight. The enzyme reaction was
stopped by boiling the sample for 15 min in a water
bath. Coagulated protein and insoluble contamination
were eliminated by centrifuging in a MiniSpin® Plus
(Eppendorf) at 14,500 rpm for 15 min at room
temperature. Muropeptides contained in the soluble
fraction were mixed with 1/3 volume of 0.5 M sodium
borate buffer (pH 9.0) and reduced with excess sodium
borohydride (NaBH4) for 30 min at room temperature.
The excess borohydride was neutralised with phosphoric
acid (dilution 1:10) to pH 3–4. Finally the samples were
filtered through Millex®-GV Filter 0.22 μm (Millipore)
units and stored at −20 °C. Reduced muropeptides were
separated and analysed by HPLC (Breeze™ 2 System,
Waters). Elution products were detected at wavelength
204 nm and identified by the retention time obtained.
The relative quantity of muropeptides present in each
sample was determined by integration of their respective
absorption areas (Breeze™ 2, Waters) and expressed as a
molar fraction (mol%) of the total content. When re-
quired, the individual peaks were collected, vacuum
dried and stored at −20 °C.
Quantification of muropeptides
Individual muropeptide M5 (monomer disaccharide
pentapeptide), M5N (anhydrous monomer disaccharide
pentapeptide), D45 (dimer disaccharide tetrapeptide-
pentapeptide) and D45N (anhydrous dimer disaccharide
tetrapeptide-pentapeptide), natural substrates necessary
for enzymatic digestion and kinetics assays, were recov-
ered from the full HPLC pattern of reduced muropep-
tides, desalted and concentrated from E. coli DV900 (a
mutant with deletion of nine PBPs and depleted D,D-
carboxypeptidase and D,D-endopeptidase activities). The
concentration of each product was quantified as a func-
tion of the mesoA2pm (DAP) amino acid content using
the methodology described by Work [31].
Lysogenization in E. coli DV900. Transformation and
expression of recombinant clones
E. coli DV900(DE3) was constructed using the λDE3 Ly-
sogenization Kit (Novagen). The transformation of each
recombinant clone (pET-PBP4HNC, pET-PBP4HN,
pET-PBP4HC) in competent lysogenic cells was carried
out by a thermal shock protocol, while overexpression of
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recombinant proteins was done as described above for
clones transformed in E. coli BL21(DE3).
In vivo PBP4 D,D-peptidase activities on macromolecular
peptidoglycan of Escherichia coli
In vivo studies of D,D-peptidase activities (D,D-carboxy-
peptidase; D,D-endopeptidase) for LMM-PBP4 on
macromolecular peptidoglycan of Escherichia coli was
carried out using bacterial cultures of recombinant con-
structs pET-PBP4HNC, pET-PBP4HN, pET-PBP4HC,
transformed into a lysogenized mutant strain E. coli
DV900(DE3), cultured with and without IPTG induc-
tion. These samples were used in the preparation and
separation of peptidoglycan, according to the protocols
mentioned above. The relative amount of monomer M5
and dimer D45 in the murein sacculus of the mutant
strain E. coli DV900 allowed us to investigate in vivo the
D,D-carboxypeptidase function (on M5) and the D,D-
endopeptidase-D,D-carboxypeptidase function (on D45)
for LMM-PBP4. Their activity was estimated from the
variation in the abundance of the substrate and product
muropeptides relative to a control sample in the HPLC
analyses of digested sacculi. The results correspond to
the mean value of three individual experiments.
In vivo PBP4 D,D-peptidase activities on macromolecular
peptidoglycan of Pseudomonas aeruginosa
For in vivo studies of D,D-peptidase activities (D,D-car-
boxypeptidase; D,D-endopeptidase) of LMM-PBP4 on
macromolecular peptidoglycan of Pseudomonas aerugi-
nosa were used murein preparations of the wild-type ref-
erence strain PA14WT under natural conditions and
after antibiotic treatment. Transformant strain
PA14WT/pHERD-PBP4 was used without induction,
under overexpression conditions [L(+)arabinose 0.2 %]
and after antibiotic inactivation for LMM-PBP4. LMM-
PBP4 inactivation was carried by treatment of the cul-
ture with cefoxitin (10 μg/ml) at 37 °C for 42 min (one
mass doubling). Enzyme activities were estimated from
the variation in the abundance of presumed substrate
and product muropeptides relative to a control sample
in the HPLC analyses. The results correspond to the
mean value of three independent experiments.
D,D-peptidase activity on natural substrates. Kinetic
studies
The D,D-carboxypeptidase activity for LMM-PBP4 of
PAO1 was assayed in vitro by monitoring the appear-
ance of the monomeric tetrapeptide (M4) in mixtures
containing increasing concentrations of monomer disac-
charide pentapeptide (M5) (14.6 μM to 227.0 μM) as
substrate, purified enzyme PBP4HC (0.57 μM) and PBS
1X pH 8.0, in a final volume of 200 μl. Reaction
mixtures were incubated at 37 °C for 150 min. D,
D-endopeptidase activity was determined using increasing
concentrations of the dimeric compound tetrapentapep-
tide (D45) (from 8.3 μM to 137.3 μM), PBP4HC protein
(0.59 μM) and PBS 1X pH 8.0. Reaction mixtures were
incubated at 37 °C for 110 min. All enzyme reactions
were terminated by boiling the samples for 2 min; they
were centrifuged at 14,500 rpm for 10 min, filtered
(Millex-GV Filter 0.22 μm, Millipore) and analysed by
HPLC. Apparent Km and Vmax values were obtained
from double-reciprocal Lineweaver-Burk plots of the
data. kcat was determined as Vmax/[E0] (where [E0] corre-
sponds to the micromolar concentration of purified
LMM-PBP4). Graphical and statistical analyses were per-
formed using the GraphPad Prism® v5.01 programme
(GraphPad Software, Inc.). The results correspond to the
mean value of experiments done in triplicate.
Three-dimensional structure
A 3D model of PBP4 from Pseudomonas aeruginosa was
generated using homology modelling procedures and the
crystal structure of PBP4a from Bacillus subtilis as tem-
plate (PDB code: 2J9P) [32]. Model coordinates were
built using the SWISS-MODEL server (available at
http://swissmodel.expasy.org) and their structural quality
was checked using the analysis programmes provided by
the same server (Anolea/GROMOS). Global model qual-
ity estimation scores are QMEAN4 raw score: 0.525 and
QMEAN4 Z-score: −0.404; these are within the accepted
range for homology-based structure models. To optimize
geometries, the model was energy-minimized using the
GROMOS96_43B1 force field implemented in DeepView
v4.1 (Swiss-PdbViewer), using 500 steps of steepest des-
cent minimization followed by 500 steps of conjugate-
gradient minimization. To evaluate the enzyme-
substrate interaction we used the molecular structure of
a fragment of synthetic pentapeptide ligand (AMV-L-
Ala-FGA-L-Lys-D-Ala-D-Ala) extracted from the PDB
3ITB archive [33]; this was modified by combined use of
the Corina v3.4, Autodock 4.2 [34] and PyMOL v1.6
programmes, followed by manual edition of the atom
coordinates to refine the interaction.
Results
The cloned molecular forms of LMM-PBP4 from PAO1 are
functional as Penicillin-Binding Proteins
The constructs for LMM-PBP4 of Pseudomonas aerugi-
nosa PAO1 [pET-PBP4HNC (PBP4HNC, NC-terminal
His · tag), pET-PBP4HN (PBP4HN, N-terminal His · tag)
and pET-PBP4HC (PBP4HC, C-terminal His · tag)], en-
abled us to evaluate the yield and behaviour of the whole
recombinant product, maintaining the sequence which
defines its signal peptide, avoiding alterations to the
structural nature of this protein and allowing it to be re-
covered in functional and constitutive conditions very
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close to those of its native organisation. After induction,
overexpression and subsequent purification assays, SDS-
PAGE and western blot analyses confirmed that only
one protein migrated to a position close to 51 kDa,
matching the molecular masses expected and calculated
for the constructs pET-PBP4HNC (55.54 kDa), pET-
PBP4HN (54.02 kDa) and pET-PBP4HC (53.38 kDa)
(Fig. 1a). Although the final products for the recombin-
ant proteins developed are identical, the forms adopted
during synthesis vary and an unprocessed variant can be
recognised with a higher molecular mass than the ma-
ture form (processed protein) in recombinant proteins
PBP4HNC and PBP4HN. In both cases the induced ma-
terial presents two bands (upper band, unprocessed pro-
tein; lower band, processed protein), while for PBP4HC
only one band is identified, which corresponds to the
mature form of the recombinant protein (Fig. 1b). The
recombinant product recovered from the purification as-
says is the mature form of the protein for the clone
pET-PBP4HC, and the unprocessed and processed forms
for the clones pET-PBP4HNC and pET-PBP4HN. This
allows us to evaluate the presence of the His · tag bound
to the amino terminal and the difficulty which this con-
figuration causes in protein maturation. Both the
precursor and the mature forms present the ability to
bind to BOCILLIN™ FL.
In vivo D,D-peptidase activity of LMM-PBP4 on macromol-
ecular peptidoglycan of Escherichia coli
D,D-peptidase activities were evaluated in vivo on
macromolecular peptidoglycan derived from a mutant of
E. coli (DV900) lacking D,D-carboxypeptidase and D,D-
endopeptidase activities and modified by lysogenization,
as shown in Fig. 2. The chromatograms obtained for
transformant lysogens not induced and induced by IPTG
confirm significant decrease of the substrates M5 and
D45, in each transformant strain subjected to induction,
in comparison with the absence of changes in the muro-
peptides profile for non-induced material. The muropep-
tides which determine a D,D-endopeptidase function are
the monomers M5 and M4, generated from substrate
D45. In this case there is a clear reduction of the sub-
strate and an increase in the amount of M4 in particular.
This effect is determined by the use of M5 as an alterna-
tive substrate for the second activity of the enzyme,
D,D-carboxypeptidase. D,D-carboxypeptidase activity
expressed with substrates D45 and M5 favours produc-
tion of D44 and M4 respectively; this fact amplifies the
a
b
Fig. 1 a Purification of LMM-PBP4. SDS-PAGE analysis of purified recombinant proteins PBP4HNC (lanes 2, 3, 4, 5), PBP4HN (lanes 6, 7, 8, 9) and
PBP4HC (lanes 10, 11, 12, 13). Lane 1, molecular weight marker (51 kDa); lanes 2, 6 and 10, flow-through; lanes 3, 7 and 11, elution with 125 mM
imidazole from Ni-NTA; lanes 4, 8 and 12, elution with 250 mM imidazole from Ni-NTA; lanes 5, 9 and 13, elution with 500 mM imidazole from
Ni-NTA.. b Identification assays for LMM-PBP4. Pattern of Bocillin™ FL binding to membrane protein extracts prepared from strains E. coli
BL21(DE3)/pET-PBP4HNC, E. coli BL21(DE3)/pET-PBP4HN and E. coli BL21(DE3)/pET-PBP4HC. Extracts from non induced cell (NI) and induced by
IPTG (IPTG) are shown. Unprocessed and mature forms of the overexpressed proteins are indicated by arrows. PBPs profile model (PBP) for
Escherichia coli is shown
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final amount of M4 monomeric product both directly
and indirectly through the occurrence of new D,D-endo-
peptidase activity on the newly generated dimeric
product-substrate D44.
In vivo D,D-peptidase activity of LMM-PBP4 on macromol-
ecular peptidoglycan of Pseudomonas aeruginosa
The peptidoglycan structure for the bacterial model
Pseudomonas aeruginosa UCBPP-PA14 was evaluated
under three conditions, native, LMM-PBP4 overexpres-
sion and antibiotic inactivation, as a function of the rela-
tive amount of global muropeptides (molar fraction for
monomeric, dimeric and trimeric constituents), unitary
components (lipoprotein, anhydrous form, monomer di-
saccharide pentapeptide, DAP-DAP bonds) and related
structural parameters (chain length, D-D/total and
crosslinking) described in Additional file 2: Table S1 (dif-
ferences greater than 10 % in the structural values ob-
tained for strains subjected to experimentation as
compared to the amounts found in reference strains
were considered significant). Under conditions of non-
expression of the dacB gene and absence of β-lactam
(cefoxitin) antibiotic treatment, the peptidoglycan com-
position for the transformant strain PA14WT/pHERD-
PBP4 as compared to the murein composition of the ref-
erence strain UCBPP-PA14 (PA14WT) presents a fall in
the levels of dimers, trimers, DAP-DAP and D-D/total;
these define an increase in the amount of monomers
and a lower percentage of crosslinking. There was also a
reduction in anhydrous forms which explains a moder-
ate increase in the chain lengths. These effects may be
interpreted as a consequence of a basal level of expres-
sion of the dacB gene in this construction. The peptido-
glycan of the transformant strain PA14WT/pHERD-
PBP4 under induction [L(+)-arabinose 0.2 %] presents
an organisation which reveals a significant decrease in
the amount of dimeric and trimeric constituents
(PA14WT/pHERD-PBP4, dimers: 21.9 mol% against
Fig. 2 D,D-peptidase activities on peptidoglycan of Escherichia coli. HPLC chromatograms of peptidoglycan obtained from strains E. coli DV900(DE3)/
pET-PBP4HNC, E. coli DV900(DE3)/pET-PBP4HN and E. coli DV900(DE3)/pET-PBP4HC, uninduced (NI) and induced by IPTG (IPTG). Chromatograms for
the lysogenized mutant strain E. coli DV900(DE3) and transformed with the expression vector pET-28b(+) are presented as controls. The following
muropeptides are identified: M3, monomer disaccharide tripeptide; M4, monomer disaccharide tetrapeptide; M5, monomer disaccharide pentapeptide;
M4N, anhydrous monomer disaccharide tetrapeptide; D44, dimer disaccharide tetrapeptide-tetrapeptide; D45, dimer disaccharide tetrapeptide-
pentapeptide; D45N, anhydrous dimer disaccharide tetrapeptide-pentapeptide; T445, trimer tetrapeptide-tetrapeptide-pentapeptide; T445N, anhydrous
trimer tetrapeptide-tetrapeptide-pentapeptide. A204, absorbance at 204 nm, arbitrary units
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29.4 mol%; trimers: 1.2 mol% against 1.9 mol%), leading
to a proportional increase in the relative abundance of
monomers (PA14WT/pHERD-PBP4, monomers: 76.8 mol%
against 67.5 mol%) and a considerable decrease in the cross-
linking levels (PA14WT/pHERD-PBP4, crosslinking: 24.3 %
against 33.4 %); the reduction in the number of anhydrous
forms is also considerable (PA14WT/pHERD-PBP4, anhyd-
rous forms: 4.4 against 7.3), which in turn defines greater
chain length (PA14WT/pHERD-PBP4, chain length: 22.2
against 13.6), in the muropeptides composition for the mu-
rein of the corresponding non-induced control strain. DAP-
DAP and lipoprotein levels do not present major changes,
the percentages of D-D/total are slightly higher, while the
values assigned to monomer disaccharide pentapeptide
present only a slight reduction (PA14WT/pHERD-PBP4,
pentapeptide: 0.3 against 0.4). Under antibiotic treatment
with cefoxitin (FOX), the structural composition of
PA14WT peptidoglycan presented an important increase in
the relative quantity of monomer disaccharide pentapeptide
(M5) (PA14WT, pentapeptide: 3.7 mol% against 0.4 mol%)
which stimulates the formation of dimers and trimers with
4–3 bonds (if the DAP-DAP levels are not affected)
(PA14WT, dimers: 37.3 mol% against 32.6 mol%; trimers:
3.4 mol% against 2.4 mol%), and as a consequence of this in-
crease there is a reduction in monomers (PA14WT,
monomers: 59.1 mol% against 63.9 mol%) and an increase
in the crosslinking percentage (PA14WT, crosslinking:
44.5 % against 37.6 %). The consequence of this efficient
blocking of all the LMM-PBPs by the β-lactam cefoxitin,
interrupting D,D-carboxypeptidase and D,D-endopeptidase
functions, is favourable to the results described. In the case
of LMM-PBP4 induction [L(+)-arabinose 0.2 %] and treat-
ment with cefoxitin, the peptidoglycan architecture of the
PA14WT/pHERD-PBP4 strain presents structural parame-
ters very close to those reported in the wild-type (cefoxitin
inhibits the function of LMM-PBP5/6 and LMM-PBP7 and
is incapable of blocking the amount of protein expressed);
this confirms that there is a reversion, as there is again a rise
in the level of monomers and a reduction in crosslinking,
defined by the expression of D,D-endopeptidase activity.
The recovery in the pentapeptide (M5) value is not very effi-
cient, since LMM-PBP4 of Pseudomonas aeruginosa appears
to be better for D,D-endopeptidase than D,D-carboxypepti-
dase (Fig. 3).
D,D-peptidase activity of LMM-PBP4 on natural muropep-
tides. Kinetic evaluation
The enzyme digestion assay for PBP4HC on the purified
and concentrated muropeptides M5 (monomer disac-
charide pentapeptide) and D45 (dimer disaccharide
Fig. 3 D,D-peptidase activities on peptidoglycan of Pseudomonas aeruginosa. HPLC chromatograms of peptidoglycan obtained from reference
strain UCBPP-PA14 (PA14WT), PA14WT/pHERD-PBP4 induced with L(+)-arabinose 0.2 %, PA14WT treated with cefoxitin (FOX), and PA14WT/
pHERD-PBP4 induced with L(+)-arabinose 0.2 % and treated with cefoxitin (FOX). The following muropeptides are identified: M3, monomer
disaccharide tripeptide; M4, monomer disaccharide tetrapeptide; M5, monomer disaccharide pentapeptide; M3L, monomer disaccharide tripeptide
associated with lipoprotein; D43, dimer disaccharide tetrapeptide-tripeptide; D44, dimer disaccharide tetrapeptide-tetrapeptide; D44N, anhydrous
dimer disaccharide tetrapeptide-tetrapeptide; T444, trimer tetrapeptide-tetrapeptide-tetrapeptide; T444N, anhydrous trimer tetrapeptide-
tetrapeptide-tetrapeptide. Arab., arabinose; A204, absorbance at 204 nm, arbitrary units
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tetrapeptide-pentapeptide), and the evaluation carried
out with HPLC, confirm the capability of this enzyme to
develop D,D-carboxypeptidase activity, since it can re-
move a D-alanine terminal from the peptide chain for
the substrate M5 and generate an increase in the prod-
uct M4 (monomer disaccharide tetrapeptide). The pro-
tein studied for its effects on dimer disaccharide D45
demonstrates its competence as an efficient D,D-endo-
peptidase, hydrolysing the peptide bond which maintains
the dimer configuration of this substrate and recovering
the expected monomer products, M5 and M4 respect-
ively. The amount of monomer disaccharide tetrapeptide
was slightly higher than the amount of monomer disac-
charide pentapeptide recovered, which demonstrates
secondary D,D-carboxypeptidase activity from the M5
generated; the same function is demonstrated by the
production of D44 (dimer disaccharide tetrapeptide-
tetrapeptide) from the original substrate D45. Enzyme
activity on anhydrous derivates M5N (anhydrous mono-
mer disaccharide pentapeptide) and D45N (anhydrous
dimer disaccharide tetrapeptide-pentapeptide) shows
very similar behaviour to that of muropeptide substrates
with no chain terminus residues, although with a
minority product profile. This helps to explain the
D,D-carboxypeptidase and D,D-endopeptidase prop-
erties of LMM-PBP4 (PAO1), Despite this, D,D-car-
boxypeptidase activity can be identified on substrate
M5 from the presence of product M4N, as well as
D,D-endopeptidase/D,D-carboxypeptidase bifunction-
ality on the dimer substrate D45N, from the recov-
ery of muropéptidos M5, M4N and M5N (products
indicating D,D-endopeptidase activity) and monomer
M4 (product derived from direct D,D-endopeptidase
activity on natural substrate D45N and D,D-carboxy-
peptidase activity on the monomer product M5)
(Fig. 4). Analysis of D,D-carboxypeptidase/D,D-endo-
peptidase activity for LMM-PBP4 on purified muro-
peptides M5 and D45 yielded kinetic constants Vmax,
Km and kcat. A lower value was found for Km on the
dimer substrate D45, as compared to the monomer
substrate M5 (> Km); furthermore the kcat levels
were 15–17 times higher for activity on substrate
D45, as compared to the activity shown on natural
substrate M5 (Additional file 2: Table S2).
Fig. 4 D,D-peptidase activity on purified muropeptides. HPLC chromatograms for digestion assays with purified recombinant protein PBP4HC on
natural substrate, M5 (monomer disaccharide pentapeptide), D45 (dimer disaccharide tetrapeptide-pentapeptide), M5N (anhydrous monomer
disaccharide pentapeptide) and D45N (anhydrous dimer disaccharide tetrapeptide-pentapeptide). The identified products are labeled: M4, monomer
disaccharide tetrapeptide; D44, dimer disaccharide tetrapeptide-tetrapeptide; M4N, anhydrous monomer disaccharide tetrapeptide. A204, absorbance
at 204 nm, arbitrary units
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3D structural homology analysis of LMM-PBP4 revalidates
D,D-endopeptidase activity
Homology simulation for the protein LMM-PBP4 of
Pseudomonas aeruginosa O1 (Fig. 5a) enables us to dis-
tinguish clearly the three motives which define it as
LMM-PBP class C, subclass C1, located in domain 1. As
in the case of its structural homologues, PBP4a of Bacil-
lus subtilis and D,D-Peptidase of Actinomadura R39,
and its functional homologue PBP4 of Escherichia coli,
for the monomer unit of LMM-PBP4 in PAO1 we con-
firmed the presence of an amino acid insert which con-
stitutes domains II and III (with domain III contained in
domain II). The active site of the protein is located in
domain I (PB domain), at the interface between 5 β
sheets and a group of α helices. It consists of the initial
segment of helix α2 (S72-K75) which is part of the
STMK sequence [which in turn includes the catalytic
serine in position 72 (* S72)], the lateral chain of a β2
sheet (V424-L429) which contains the KTG conserved
motive, and a small loop which connects helices α3-α4
(Y314-N317) and incorporates a third SNN conserved
sequence (Fig. 5b). Residues from domains II and III
take part of the roof of a cavity which communicates at
depth with the inner catalytic serine. The estimated di-
mensions of this U-shaped slit on the surface of the pro-
tein (depth 24.6 Å, width 19.6 Å) are very close to those
described for the slit of the active site on the functional
homologue PBP4 of E. coli (depth 20 Å, width 15 Å)
(Fig. 5c) [35]. Molecular simulation of the coupling of
the mimetic pentapeptide substrate AMV-L-Ala-FGA-L-
Lys-D-Ala-D-Ala in the cavity of the active site for
LMM-PBP4 of PAO1 validates its size and tolerance of
Fig. 5 3D model for LMM-PBP4 of PAO1. a Homology modeling of monomer Pseudomonas aeruginosa LMM-PBP4 (surface representation). The different
domains are presented in brown (domain I), red (domain II) and green (domain III). b Domain I and conserved motifs in the active site of LMM-PBP4. For
the first conserved sequence SxxK (STMK; *S72, catalytic serine at position 72), located at the beginning of α2 helix, residues are represented by an intense,
blue, cyan and pale blue color, respectively. The second conserved sequence SxN (SNN), located in a short loop between α3-α4, is represented by a
gradient of colors derived from green. The three residues of the third conserved motif KTG, located in a β sheet (β2) are represented on dark red, red and
orange, respectively. c Location for synthetic peptide AMV-L-Ala-FGA-L-Lys-D-Ala-D-Ala (linear representation) is indicated within the active site model for
LMM-PBP4. Estimated distances for depth, height and width in this cavity are shown. d Putative residues constituents for the specific subsite in the active
site of LMM-PBP4. Location of the amino acid lysine (L-Lys) of the synthetic substrate AMV-L-Ala-FGA-L-Lys-D-Ala-D-Ala, the residue equivalent to
mesoA2pm in natural muropeptides, is indicated. Each amino acid has been labeled and highlighted by a color (aspartic acid 162, blue; leucine 369, green;
threonine 428, yellow; leucine 429, red; asparagine 430, gray). AMV, methyl 2-(acetylamino)-3-O-[(1R)-1-carboxyethyl]-2-deoxy-beta-D-glucopyranoside; FGA,
gamma-D-glutamic acid
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larger ligands; it also allows us to identify the constituent
amino acids of a sub-site in the catalytic pocket [aspartic
acid 162 (D162), leucine 369 (L369), threonine 428
(T428), leucine 429 (L429) and asparagine 430 (N430)]
(Fig. 5d). They are related (as described for equivalent
amino acids in homologous proteins) with the specificity
for its substrate, by recognition of the terminal group
NH3
+-CH-COO− for the amino acid mesoA2pm of the
peptide chain. Actually, in the molecular model, the L-
Lys of the mimetic pentapeptide substrate is linked to
the protein by specific interaction with three of those
residues: the carbon chain of L-Lys interact with leucine
369 (L369), and the NH3
+ terminal of L-Lys interact with
the COO− group of aspartic acid 162 (D162) (mainly)
and the CO group of asparagine 161 (N161).
Discussion
In Pseudomonas aeruginosa, the inactivation of AmpD
and point mutations in AmpR and DacB (LMM-PBP4)
have been found to lead to AmpC overexpression; the
shared aspect of each of these three proteins is the func-
tional requirement for concomitant maturation of its
peptidoglycan. These two processes (AmpC overexpres-
sion and peptidoglycan maturation) are directly inter-
connected by the pathway for the efficient recycling of
muropeptides [36–38]. AmpD and DacB are not re-
quired for overexpression. A functional AmpR is re-
quired, but on the contrary, it is the mutational
inactivation of AmpD or DacB what produces the over-
expression. Recent studies stressed the complexity of
this relationship, in which the role of the amidase AmpD
is definitely known, the role of the transcriptional regu-
lator AmpR is partially recognised with some degree of
certainty, while researchers have speculated on the func-
tion of LMM-PBP4 based on information available for
coding gene of this protein in the PAO1 and UCBPP-
PA14 strains. The putative nature of this information
has been partly resolved in recent research showing, for
example, that LMM-PBP4 of Pseudomonas aeruginosa
exercises control over the function of AmpR, presum-
ably as a result of its ability to create or destroy a par-
ticular muropeptide chain subunit [21, 23, 38]. A study
aimed to characterize the role of LMM-PBPs in peptido-
glycan composition, β-lactam resistance, and AmpC
regulation, indicated that PBP4 play a significant role as
D,D-carboxipeptidase only when PBP5 is absent; on the
other hand, the peptidoglycan structure of PBP4 and
PBP7 single and double mutants showed that these pro-
teins have D,D-endopeptidase activity [39]. A recent
publication explored the catalytic capability of this en-
zyme through direct digestion assays on peptidoglycan
sacculus and a variety of synthetic substrates, finding
that LMM-PBP4 (soluble form with no signal peptide)
exerts D,D-carboxypeptidase and D,D-endopeptidase
activity, just like its functional homologue PBP4 of
Escherichia coli (although this protein is not involved in
resistance to antibiotics) [38]. In an attempt to confirm
the above with a dynamic experimental model in vivo
using natural substrates, we investigated the function for
LMM-PBP4 of Pseudomonas aeruginosa initially using
digestion assay on macromolecular peptidoglycan de-
rived from E. coli DV900(DE3), a lysogenized mutant
strain (CS802-2 Δpbp4B) with deletions in coding gene
for all class C LMM-PBPs, as well as AmpC. This pro-
vided a biological system with structural organisation of
the cell wall which was particularly favourable for study-
ing D,D-carboxypeptidase and D,D-endopeptidase activ-
ities. Variations in the relative abundance of
muropeptides enabled us to identify a significant dimin-
ution of the substrates M5 and D45, in each transfor-
mant strain subjected to induction, in comparison with
the absence of changes in the muropeptides profile for
non-induced material. Starting with substrate D45, the
increase in the monomeric products M5 and particularly
M4 (effect determined by the provision of M5 as an al-
ternative substrate for secondary D,D-carboxypeptidase
activity) define a D,D-endopeptidase function for LMM-
PBP4. This does not appear to be affected by the pres-
ence of a D-alanine residue in position 5 for an acceptor
peptide chain in dimeric muropeptides. The presence of
the minority product D44 (new D,D-endopeptidase ac-
tivity on the dimeric substrate D44 amplifies the final
amount of monomeric product M4) and M4 confirms
D,D-carboxypeptidase activities on substrates D45 and
M5 respectively. The lower relative abundance of D44,
compared to the levels of M5 and M4 recovered from
substrate D45, eliminates the possibility that LMM-PBP4
of PAO1 carries out an initial D,D-carboxypeptidase ac-
tivity. A smaller reduction in D45N (anhydrous dimer
disaccharide tetrapeptide-pentapeptide), T445 (trimer
tetrapeptide-tetrapeptide-pentapeptide) and T445N (an-
hydrous trimer tetrapeptide-tetrapeptide-pentapeptide)
represents an important extension of substrate specifi-
city in both activities (particularly D,D-endopeptidase
activity). It has been suggested that the presence of 1,6-
anhydroMurNAc residue might have a significant
implication for D,D-carboxypeptidase/D,D-endopeptid-
ase eactions, given the smaller reduction in anhydrous
D45N-T445N substrates under muropeptides D45-T445.
This hypothesis would appear to be incorrect, in view of
the presence of a smaller but detectable amount of prod-
uct M4N (proceeding from D,D-endopeptidase activities
for anhydrous dimeric substrate D45N and D,D-car-
boxypeptidase activities on anhydrous monomer M5N)
in each muropeptides profile generated from induced ma-
terial. The above shows the simultaneous bifunctionality of
D,D-endopeptidase/D,D-carboxypeptidase exerted in vivo
on macromolecular peptidoglycan for each of the
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recombinant proteins for LMM-PBP4 of PAO1
(PBP4HNC, PBP4HN and PBP4HC) expressed in the strain
of Escherichia coli tested. Cloning of the coding gene for
LMM-PBP4 of PAO1 in expression vectors compatible with
Pseudomonas aeruginosa enabled us to design an experi-
ment to investigate the modulating role of this LMM-PBP
in the molecular integrity of the cell wall for this bacterial
model. The organisation of the peptidoglycan for the wild-
type strain UCBPP-PA14, containing the recombinant con-
struct for LMM-PBP4 (pHERD-PBP4), under induc-
tion shows a reduction in the amount of dimeric
and trimeric constituents, leading to a proportional
increase in the quantity of monomers and an im-
portant reduction in crosslinking, as well as a fall in
the number of anhydrous forms and a smaller re-
duction in the levels of M5 (monomer disaccharide
pentapeptide). These results are consistent with the
occurrence of a main D,D-endopeptidase activity
and a secondary D,D-carboxypeptidase activity, pro-
duced by the overexpression of LMM-PBP4 in this
bacterial system; the same was demonstrated in a
previous study, in which the effect of LMM-PBP4
overproduction on the murein synthesized in vivo
for the model Escherichia coli presented results with
a similar tendency, with low level of crosslinking in
(DD)-D-Ala-DAP peptide bridges, an increase in the
quantity of monomers and a reduction in the num-
ber of dimers, trimers and tetramers. This compos-
ition reflects the exclusive D,D-endopeptidase/D,D-
carboxypeptidase functions exercised by LMM-PBP4
of E. coli and involved in the turnover of the pep-
tide crosslinking of their peptidoglycan [40]. A third
group of studies, intended to evaluate direct D,D-
peptidase activity for the purified PBP4HC on nat-
ural muropeptides M5, D45, M5N and D45N, con-
firm that LMM-PBP4 (PAO1) is capable of exert
D,D-endopeptidase/D,D-carboxypeptidase catalytic
functions. Jointly with these digestion assays, and as
a way of establishing a definite conclusion on the
predominant enzyme activity for LMM-PBP4, we in-
vestigated the individual behaviour of each activity
by estimating the kinetic parameters Vmax, Km and
kcat. A constant Km of 71.9 ± 2.1 μM for the D,D-
carboxypeptidase activity of LMM-PBP4 on natural sub-
strate M5, as compared to an estimated value for Km (Km
20.4 ± 1.6 μM) for PBP4 of Escherichia coli (functional
orthologue for LMM-PBP4 of PAO1) on synthetic sub-
strate N-acetylmuramyl-pentapeptide (structurally closer
to M5) [13], defines lower D,D-carboxypeptidase behav-
iour for LMM-PBP4. The identification of lower values of
Km of LMM-PBP4 (PAO1) for D45 reflects the greater af-
finity between this protein and its dimeric substrate, and a
minor presence of the elution product D44, exclude the
initial occurrence of D,D-carboxypeptidase activity. These
data, together with the much higher catalytic effectiveness
values (kcat) found for LMM-PBP4 activity on dimeric
substrate D45 than the kcat values for this protein on nat-
ural substrate M5, confirm that D,D-endopeptidase activ-
ity is predominant for LMM-PBP4 of Pseudomonas
aeruginosa O1. Finally, analysis of the structural model for
the monomeric unit of LMM-PBP4 in PAO1 evidence a
trimodular organisation of this enzyme (presence of a
transpeptidase domain associated with two other do-
mains), with a Russian doll (matryoshka) integration
model for each module (the third domain included in the
second which is itself contained in the first) and a very
similar orientation to that described for structural homo-
logues PBP4a of Bacillus subtilis, D,D-peptidase of Actino-
madura R39 and the functional homologue PBP4 of
Escherichia coli [32, 35, 41]. On the back face of domain
II, opposite the contact surface with domain I (PB), three
residues of lysine and four of arginine expose a positively
charged area and form a bonding mechanism to the in-
ternal membrane which is an alternative to the electro-
static and polarity interactions defined for the carboxyl
terminal in this protein. A similar surface has been de-
scribed for domain II of PBP4a of B. subtilis and D,D-pep-
tidase of Actinomadura R39, however the presence of
residues of this kind has not been recognised for LMM-
PBP4 in the Escherichia coli bacterial system [32, 41]. Do-
main III with a less rigid architecture, presents a segment
which forms an integral part of the active site on this pro-
tein. Comparison with related enzymes shows that domain
I for LMM-PBP4 of PAO1 contains the necessary groups
to activate catalytic serine S72 (STMK, SNN, KTG) and to
carry out a nucleophile attack on the substrate. The resi-
dues involved in the acetylation and deacetylation mecha-
nisms by PBPs have not been clearly identified, however
in our case, for the first process, a lysine in position 75
(K75) is probably the priority structural amino acid. The
constituent residues of domains II and III determine a
cavity which communicates with the catalytic serine of the
active centre, with estimated width, depth and height
which would favour access of small molecules (antibiotics)
and longer substrates, as described in other members of
this sub-class of proteins. Our three-dimensional model
highlights the orientation and ordering of the residues of
domain III at the entrance of the slit to the active site,
which appears to support the idea of the function of this
domain in steric control of access by the substrate, a com-
petence which has not been confirmed but has been de-
duced for the homologue protein PBP4 of E. coli [35]. The
positional equivalence demonstrated between residues in
the active site of LMM-PBP4 in PAO1, particularly aspar-
tic acid in position 162 (D162) and asparagine in position
430 (N430), with amino acids conserved and defined as
constituents of a specific sub-site in the catalytic pocket of
homologue proteins PBP4 of E. coli (D155, Q422), PBP4a
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of B. subtilis (D145, S416) and D,D-peptidase in Actino-
madura R39 (D142, S415), involved in the specificity by
their substrate, through recognition of a residue in pos-
ition 3 (mesoA2pm) of the peptide chain, may constitute a
distinguishing precedent, in terms of substrate requirement,
between bifunctional proteins with D,D-carboxypeptidase/
D,D-endopeptidase activities and monofunctional proteins
with D,D-carboxypeptidase or D,D-transpeptidase activities
[13]. It should be noted that for the structural model of
PBP4a in B. subtilis, a threonine in position 394 (T394)
constitutes an amino acid residue with the capability of es-
tablishing a hydrogen bridge with T412 (conserved motive
KTG), contributing to the network of bonds which
strengthen the active site. This bonding structure has been
recognised in an equivalent position in other representa-
tives of LMM-PBPs, class C, subclass C1. However, in
PBP5, PBP6 and PBP6b of E. coli (proteins with an exclu-
sive D,D-carboxypeptidase function), an arginine residue
occupies this position, acting as a steric impediment to the
positioning of a larger substrate than the methyl group of
the last D-alanine in the peptide chain (the presence of a
small residue like threonine leaves a free space which could
receive the peptide chain of a second strand of peptidogly-
can) [32]. In our simulation for LMM-PBP4 of Pseudo-
monas aeruginosa, a threonine amino acid (T386) in a
position which coincides with the location of T394 in Bacil-
lus subtilis, together with the structural data given above,
could represent constitutive information highlighting the
occurrence of the D,D-endopeptidase function.
Conclusions
This study confirms in vivo the D,D-carboxypeptidase/
D,D-endopeptidase bifunctionality of LMM-PBP4 of
Pseudomonas aeruginosa on macromolecular peptidogly-
can in two models, Escherichia coli and Pseudomonas
aeruginosa. It highlights the occurrence of D,D-endo-
peptidase activity as the principal activity on these sub-
strates. Kinetic assays on natural muropeptides allowed
us to confirm both these hydrolytic capabilities and to
define catalytic D,D-endopeptidase activity as predomin-
ant. This competence is supported structurally by the
composition and dimensions of the active site, obtained
by molecular modelling of this protein. This description
of the function and conformation of LMM-PBP4 consti-
tutes a new perspective which supports the proposal of
this protein as a potential hydrolase-autolysin associated
with peptidoglycan maturation and recycling, The fact
that mutant PBP4 induces AmpC, may indicate that a
putative muropeptide subunit product of the DD-EPase
activity of PBP4 could be a negative regulator of the
pathway, and this makes a significant contribution to
further understand the regulatory pathways for the in-
duction and constitutive hyperproduction of chromo-
somal AmpC β-lactamase on Pseudomonas aeruginosa.
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